A vaccine that induces immune responses to a wide spectrum of influenza virus strains and subtypes has produced strong and durable results in early-stage clinical trials in humans, Mount Sinai researchers have found.
If authorized for quantitative use, the assay could be used to provide a numeric result for the concentration of neutralizing anti-COVID-19 antibodies in plasma.
By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs.
– Kantaro Biosciences partners with Bio-Techne for manufacturing and global kit distribution
– Scaled kit production to enable clinical laboratories to conduct 10M tests per month is planned to begin in July